Brief Title
Possible New Therapy for Advanced Cancer
Official Title
A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma
Brief Summary
IL-13-PE is a chemical similar to one made by the body that is connected to a toxin to specifically attack cancer cells. Researchers want to look at different doses of IL-13-PE to find one that may be safe and effective against cancer that has returned, spread to other organs, or that cannot be surgically removed. Participants will receive physical exams and report side effects. Blood and urine samples will be collected. Imaging studies, tissue samples, and other tests will be used to study the tumor before the start of treatment and during the study. IL-13-PE therapy will be given to each participant on days 1, 3 and 5 of each monthly cycle for up to 4 monthly cycles. The study will be done in two parts, with a six-month period between them. If the cancer continues to grow, participants will stop taking IL-13-PE. If the cancer continues to shrink or not grow the study will continue, even into a follow-up period after the second part of the study. The first part of this study will determine how much IL-13-PE can be tolerated. For this part, the study is recruiting adult patients with various types of cancer. After six participants have taken the lowest dose with no more than one experiencing dose-limiting toxicity, two participants may begin the study taking the medium dose. If they tolerate the medium dose for a month, up to four more may begin at that dose. When at least three participants have tolerated the medium dose, two may attempt the highest dose. When they have tolerated the highest dose for one monthly cycle, 1-4 more may begin the study, receiving the highest dose. Adrenal cortex cancer (ACC) is a rare tumor in the gland above the kidney. It affects only 1-2 people per million each year and causes hormone problems. This tumor affects children under age 5 and adults aged 30-40, causing death within five years for up to 80% of them. During the second part of the study, all participants will be ACC patients. They will receive the highest dose tolerated during Part 1 on days 1, 3, and 5 of each monthly cycle for up to four months.
Study Phase
Phase 1
Study Type
Interventional
Primary Outcome
Maximum tolerated dose of IL-13-PE
Secondary Outcome
Percentage of participants with clinically significant abnormal findings on physical examination
Condition
Adrenocortical Carcinoma
Intervention
IL-13-PE
Study Arms / Comparison Groups
Part 1- 1 μg/kg
Description: Up to 6 participants receiving IL-13-PE 1 μg/kg (rounded down to the nearest vial size within 10% of the calculated dose), intravenous (IV), Days 1, 3 and 5 in each monthly cycle for up to 4 cycles
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
9
Start Date
December 2012
Completion Date
September 2014
Primary Completion Date
March 2014
Eligibility Criteria
Inclusion Criteria: - Has measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria at presentation - Has failed standard treatment - Has met protocol-specified criteria for qualification and contraception - Has voluntarily consented to participate and provided written informed consent prior to any protocol-specific procedures Exclusion Criteria: - Has history or current use of over-the-counter medications, dietary supplements, or drugs outside protocol-specified parameters - Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: - the safety or well-being of the participant or study staff - the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding) - the analysis of results
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Electron Kebebew, M.D., ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT01832974
Organization ID
13-C-0046
Secondary IDs
13-C-0046 D
Responsible Party
Sponsor
Study Sponsor
INSYS Therapeutics Inc
Collaborators
National Institutes of Health (NIH)
Study Sponsor
Electron Kebebew, M.D., Principal Investigator, National Institutes of Health (NIH)
Verification Date
April 2015